Target intelligence / Profile preview

Prostaglandin E receptor 3 isoform 4 (EP3-IV) (EP3-IV)

Target
EP3-IV
Molecular classification
G protein-coupled receptor, Rhodopsin-like GPCR, Prostanoid receptor, Receptor
01

Overview

Prostaglandin E receptor 3 (PTGER3), specifically the splice variant IV, is a G protein-coupled receptor (GPCR) that serves as a high-affinity receptor for Prostaglandin E2 (PGE2) (UniProt P43115). This receptor is notable for its extensive C-terminal alternative splicing, which allows for diverse G-protein coupling and varying levels of constitutive activity (PubMed: 8316106). Isoform IV is particularly distinct because it can couple to multiple G-proteins, including Gi, Gs, and G12/13, thereby influencing adenylate cyclase activity and Rho-mediated pathways (IUPHAR/BPS Guide to Pharmacology). It is involved in a wide range of physiological functions such as inhibiting gastric acid secretion, modulating neurotransmitter release, and regulating smooth muscle tone in the vasculature and airways (PubMed: 7534331). In clinical contexts, PTGER3 is a target for drugs like misoprostol, used for gastric protection and labor induction, and is implicated in conditions like inflammatory pain and cardiovascular disorders (PubChem CID 5282387). Research into isoform-specific signaling is crucial for developing selective therapies that can target specific pathological processes without broad systemic side effects.

Other names
PTGER3 splice variant IVEP3-4Prostanoid EP3 receptor isoform 4PGE receptor EP3 subtype isoform 4PTGER3 isoform d
02

Mechanism of action

Agonists bind to the receptor to activate G-protein signaling pathways (primarily Gi, but also Gs or G12/13 for this specific isoform), leading to the modulation of second messengers like cAMP and calcium, while antagonists block these interactions to prevent pathological signaling.

03

Biological functions

Signal transductionSmooth muscle contractionInhibition of adenylate cyclaseRegulation of neurotransmitter releaseGastric acid secretion inhibitionPlatelet aggregation
04

Disease associations

InflammationPainCardiovascular diseaseGastric ulcerFeverOveractive bladder
05

Safety considerations

Gastrointestinal distress (diarrhea)Uterine contraction and potential pregnancy lossCardiovascular effectsFever modulation
06

Interacting drugs

Misoprostol

5 more in the full profile.

07

Biomarkers

PTGER3 mRNA expressionEP3 protein levels in tissuePGE2 concentration in synovial fluid

Beyond the preview

Go deeper on Prostaglandin E receptor 3 isoform 4 (EP3-IV) (EP3-IV).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prostaglandin E receptor 3 isoform 4 (EP3-IV) (EP3-IV).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call